WallStreetZenWallStreetZen

NASDAQ: NIVF
Newgenivf Group Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NIVF stock forecasts and price targets.

Forecast return on equity

Is NIVF forecast to generate an efficient return?

Company
17.74%
Industry
-90.16%
Market
237.6%
NIVF's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NIVF forecast to generate an efficient return on assets?

Company
14.66%
Industry
11%
NIVF is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NIVF earnings per share forecast

What is NIVF's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$8.11
Avg 2 year Forecast
$32.39
Avg 3 year Forecast
$12.11

NIVF revenue forecast

What is NIVF's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$66.5M
Avg 2 year Forecast
$174.9M
Avg 3 year Forecast
$277.9M

NIVF vs Medical Care Facility Stocks

TickerPricePrice TargetUp/downsideConsensus
NIVF$0.56N/AN/A
SRXH$0.18N/AN/A
AMS$2.15N/AN/A
BMGL$0.83N/AN/A
CCM$4.45N/AN/A
View Top Medical Care Facility Stocks

Newgenivf Group Stock Forecast FAQ

What is NIVF's earnings growth forecast for 2026-2028?

(NASDAQ: NIVF) Newgenivf Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Care Facilities industry's average forecast earnings growth rate of 19.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 106.26%.

Newgenivf Group's earnings in 2026 is N/A.On average, 3 Wall Street analysts forecast NIVF's earnings for 2026 to be $3,491,249, with the lowest NIVF earnings forecast at $3,354,337, and the highest NIVF earnings forecast at $3,593,933. On average, 3 Wall Street analysts forecast NIVF's earnings for 2027 to be $13,943,038, with the lowest NIVF earnings forecast at $13,396,252, and the highest NIVF earnings forecast at $14,353,127.

In 2028, NIVF is forecast to generate $5,212,720 in earnings, with the lowest earnings forecast at $5,008,300 and the highest earnings forecast at $5,366,035.

If you're new to stock investing, here's how to buy Newgenivf Group stock.

What is NIVF's revenue growth forecast for 2026-2028?

(NASDAQ: NIVF) Newgenivf Group's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of 6.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 57.35%.

Newgenivf Group's revenue in 2026 is N/A.On average, 3 Wall Street analysts forecast NIVF's revenue for 2026 to be $28,632,202, with the lowest NIVF revenue forecast at $27,509,353, and the highest NIVF revenue forecast at $29,474,338. On average, 3 Wall Street analysts forecast NIVF's revenue for 2027 to be $75,288,530, with the lowest NIVF revenue forecast at $72,335,025, and the highest NIVF revenue forecast at $77,501,505.

In 2028, NIVF is forecast to generate $119,655,677 in revenue, with the lowest revenue forecast at $114,967,096 and the highest revenue forecast at $123,177,494.

What is NIVF's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: NIVF) forecast ROA is 14.66%, which is higher than the forecast US Medical Care Facilities industry average of 11%.

What is NIVF's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NIVF) Newgenivf Group's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that NIVF's EPS will be $8.11 for 2026, with the lowest EPS forecast at $7.79, and the highest EPS forecast at $8.35. On average, analysts forecast that NIVF's EPS will be $32.39 for 2027, with the lowest EPS forecast at $31.12, and the highest EPS forecast at $33.34. In 2028, NIVF's EPS is forecast to hit $12.11 (min: $11.63, max: $12.46).

What is NIVF's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: NIVF) forecast ROE is 17.74%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.